Maintenance Lab Monitoring for Kesimpta (Ofatumumab)

Key Monitoring Requirements

• Unlike traditional disease-modifying antirheumatic drugs that require frequent CBC and LFT monitoring every 2-4 weeks initially, then every 8-12 weeks, Kesimpta does not require routine hematologic or hepatic laboratory monitoring, as per guidelines from the American College of Rheumatology 1